BNGO - CIK 0001411690
Bionano Genomics, Inc. (BNGO) reported net income of -$26.39M for fiscal year 2025, as filed in its audited annual report with the SEC.
| Fiscal year | Net Income | Change |
|---|---|---|
| FY 2025 | -$26.39M | +76.4% |
| FY 2024 | -$112.02M | +51.8% |
| FY 2023 | -$232.49M | -75.3% |
| FY 2022 | -$132.60M | -83.1% |
| FY 2021 | -$72.44M | -76.2% |
| FY 2020 | -$41.11M | -37.9% |
| FY 2019 | -$29.82M | -61.2% |
| FY 2018 | -$18.50M | +20.8% |
| FY 2017 |
Bionano Genomics, Inc. (BNGO) reported net income of -$26.39M for fiscal year 2025, as filed in its audited annual report with the SEC.
Between fiscal 2017 and fiscal 2025, Bionano Genomics, Inc.'s net income declined from -$23.37M to -$26.39M.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| -$23.37M |
| - |